Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
/in International Publications, Malignant Melanoma /von 2008-08-22 / Cancer Immunol. Immunother. 2009 Jan;58(1):1-14Recombinant Newcastle disease virus as a vaccine vector for cancer therapy
/in International Publications, Newcastle Disease Virus /von 2008-08-19 / Mol. Ther. 2008 Nov;16(11):1883-90Novel therapeutic strategies for treating esophageal adenocarcinoma: the potential of dendritic cell immunotherapy and combinatorial regimens
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2008-08-12 / Hum. Immunol. 2008 Oct;69(10):614-24A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas
/in International Publications, Soft Tissue Sarcoma /von 2008-08-01 / Clin. Cancer Res. 2008 Aug;14(15):4850-8A two-state cell damage model under hyperthermic conditions: theory and in vitro experiments
/in Hyperthermia, International Publications, Prostate Cancer /von 2008-08-01 / J Biomech Eng 2008 Aug;130(4):041016Regional hyperthermia of the abdomen in conjunction with chemotherapy for peritoneal carcinomatosis: evaluation of two annular-phased-array applicators
/in Gastric Cancer, Hyperthermia, International Publications /von 2008-08-01 / Int J Hyperthermia 2008 Aug;24(5):399-408Dendritic cell vaccines in metastasized malignant melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2008-08-01 / G Ital Dermatol Venereol 2008 Aug;143(4):235-50Oncolytic virotherapy as a personalized cancer vaccine
/in International Publications, Newcastle Disease Virus /von 2008-08-01 / Int. J. Cancer 2008 Aug;123(3):493-9Virus combinations and chemotherapy for the treatment of human cancers
/in International Publications, Newcastle Disease Virus /von 2008-08-01 / Curr. Opin. Mol. Ther. 2008 Aug;10(4):371-9
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution